Skin toxicity related to targeted therapy

Interactive e-learning on skin toxicity related to targeted therapy in GI and liver cancer

This educational e-learning will help nurses and physicians alike better understand skin reactions to targeted therapy in GI and liver cancers. The course aims to support the prevention, diagnosis and management of these dermatologic adverse events and encourages a multidisciplinary team approach to optimise patient care.

Find out more about the programme in this short video:

Developed by an expert multi-disciplinary faculty:

  • Natasha Pinheiro, nurse practitioner from New York, USA (GI Nurses CONNECT)
  • Dr Catherine Frenette, hepatologist from San Diego, USA (HCC CONNECT)
  • Dr Victor Hugo Fonseca de Jesus, medical oncologist from São Paulo, Brazil (GI CONNECT)
  • Dr Nicole LeBoeuf, dermatologist from Boston, USA

Start your learning journey now:

  • Launch your interactive e-learning: https://checkpoint.cor2ed.com
  • Download an educational slide deck to capture the key content
  • Obtain your own copy of our helpful leaflet to give to your patients
CME credits that you may recognise are available by completing this e-learning course; European CME Credits (ECMECs), AMA PRA Category 1 CreditsTM and American Board of Internal Medicine (ABIM) MOC credit. You may find you are able to use these as evidence for your own local system of nursing CME credits.

Targeted therapies result in a higher incidence of dermatologic adverse events than do non-targeted therapies. Skin toxicity may require a change in dosing, can result in both physical and psychological discomfort or pain, and can raise the risk of total treatment interruption which may lead to a worsening of the patient’s cancer. An approach to pre-emptively address and treat potential skin toxicities may improve patients’ quality of life, therefore allowing them to stay on therapy for longer. Best practice amongst healthcare professionals recommends working as a multidisciplinary team to prevent, diagnose, and manage skin toxicities associated with targeted therapy in cancers such as hepatocellular carcinoma, colorectal cancer, pancreatic cancer, neuroendocrine tumours, gastric cancer and GIST.

Understanding adverse skin reactions to targeted therapy in GI and liver cancers; knowing how to prevent and manage skin toxicities associated with targeted therapies in GI and liver cancers; and being able to involve a multidisciplinary team in the prevention, diagnosis, and management of skin toxicities associated with targeted therapies. These are all key objectives of this educational e-learning course which is aimed at any healthcare professional treating and managing patients prescribed with targeted therapies for liver and GI cancers.

The course has been created as a collaboration between GI CONNECT, GI Nurses CONNECT and HCC CONNECT, supported by an independent educational grant from Bayer.